VSTM logo

Verastem Inc

VSTM

Build a strategy around VSTM

Accountable AI Logo

Verastem Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-30

Snapshot

  • Negative equity (-15.5M) with 89.5M debt - balance sheet impaired. Cash of 137.7M covers ~1 year at current -133M TTM burn rate.[Common Stockholders Equity]
  • Revenue 62% 3Y CAGR (TTM 13.4M) but operating loss of -160M dwarfs sales. R&D spend of 104M is 7.8x revenue.[Total Revenue 3Y Growth TTM]
  • P/S of 41x vs industry median 4.1x - trading at 10x premium despite negative margins and equity.[P/S Ratio]

Watch Triggers

  • Cash and Equivalents: Falls below 75M or burn rate accelerates beyond -150M annuallyTriggers forced dilutive financing at distressed terms
  • Total Revenue TTM: Quarterly revenue exceeds 5M (20M annualized run rate)Would signal commercial inflection reducing financing pressure
  • Issuance of Capital Stock: Any equity raise announcementDilution magnitude determines equity value preservation

Bull Case

83% gross margin (TTM) shows product economics work if pipeline succeeds. Revenue grew 62% 3Y CAGR from low base - commercial traction emerging.

Gross MarginTotal Revenue 3Y Growth TTM

Working capital of 94M and current ratio of 2.6x (154M/60M) provides near-term operational flexibility for clinical execution.

Working CapitalCurrent Assets

Bear Case

Negative equity (-15.5M) and 89.5M debt create existential dilution risk. Any capital raise at 552M market cap severely dilutes shareholders.

Total EquityTotal DebtMarket Cap TTM

FCF of -141M TTM exceeds cash of 138M. Without financing, operations cease within 12 months. 5Y revenue CAGR of -32% shows prior struggles.

Free Cash Flow TTMCash and EquivalentsTotal Revenue 5Y Growth

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
25%

Leverage VSTM's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Binary catalyst: regulatory/clinical outcomes will determine survival within 12 months

3-12mlow
  • Cash runway of ~12 months at -133M annual burn
  • R&D of 104M TTM signals late-stage pipeline investment
  • Negative equity requires capital raise or partnership
Cash 137.7M vs FCF -140.9M TTMOperating loss -160M on 13.4M revenueTotal equity -15.5M, debt 89.5M

Valuation Context

Caveats

Public Strategies Rankings

See how Verastem Inc ranks across different investment strategies.

Leverage VSTM's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.